Page 11 - Trending_051418

Trump plan for drug prices won’t include direct negotiations
By MATTHEW PERRONE, AP Health Writer
WASHINGTON (AP) — After more than a year of bold promises, President Donald Trump is unveiling his plans for reducing drug prices. But they don’t include a key cam- paign pledge to use the buying power of the government’s Medicare program to negotiate lower costs for seniors.
In advance of Trump’s speech on his
plans Friday, officials previewed a raft of old and new ideas to increase competition and improve transparency in the notoriously com- plex drug pricing system with the ultimate aim of wringing more savings for consumers.
It’s an approach that avoids a direct con- frontation with the powerful pharmaceutical lobby, but it could also underwhelm Ameri- cans seeking relief from escalating prescrip- tion costs.
“Consumers are ultimately going to be
the judge of this announcement,” said Dan Mendelson, a health care consultant. “If they don’t address the cost that patients see at the pharmacy counter it’s not going to be seen as responsive.”
A majority of Americans say passing laws to bring down prescription drug prices should be a “top priority” for Trump and Congress, according to recent polling by the Kaiser Family Foundation.
As a candidate, Trump railed against the pharmaceutical industry, accusing companies of “getting away with murder.” But as presi- dent he has shied away from major reforms and staffed his administration with appointees who have deep ties to the industry, including health secretary, Alex Azar, a former top exec- utive at Eli Lilly.
Azar and other Trump officials have described the problem in stark terms and promised bold action.
“Every incentive is toward higher list prices because everyone in the system gets a cut off that list price except the patient,” said Azar, speaking on “Fox and Friends” on Friday morning.
He said one new proposal would allow senior citizens enrolled in Medicare who hit the catastrophic period to pay nothing out of
pocket, “so really relieve a huge burden on our senior citizens.”
Parts of the plan were previously released in the president’s budget proposal and would re- quire action by Congress. Those steps include: requiring insurers to share rebates from drug companies with Medicare patients and chang- ing the way Medicare pays for high-priced drugs administered at doctors’ offices.
Trump staffers said the new steps coming Friday could be taken immediately without congressional lawmakers, who are mainly focused on November elections. The measures aim to increase competition, create incentives for drugmakers to lower initial prices and stop foreign governments from “freeloading” off U.S. pharmaceutical research. But the officials gave few specifics.
Public outrage over drug costs has been growing for years as Americans face pric-
ing pressure from multiple sources: New medicines for life-threatening diseases often launch with prices exceeding $100,000 per year. And older drugs for common ailments like diabetes and asthma routinely see price hikes around 10 percent annually. Meanwhile Americans are paying more at the pharmacy counter due to health insurance plans that require them to shoulder more of their pre- scription costs.
Trump officials have hinted for weeks that the plan, in part, will untangle the convolut- ed system of discounts and rebates between drugmakers and insurers, pharmacy benefit managers and other health care middlemen. FDA Commissioner Scott Gottlieb — another Trump official with industry ties — says this lack of transparency creates perverse incen- tives in which drugmakers and other health care companies all benefit from rising prices.
“Right now, we don’t have a truly free mar- ket when it comes to drug pricing, and in too many cases, that’s driving prices to unafford- able levels for some patients,” Gottlieb said in a speech last week.
Experts who study drug pricing are encour- aged that the discussion has moved on from outrage to more sophisticated proposals.
“This is progress and I think there’s no question that opening up the machine to
make it more clear how it works will lead to change — hopefully to constructive change,” said Dr. Peter Bach, director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes.
But others warn there is no guarantee that unraveling the current pricing-setting bureau- cracy will lead to lower prices, because it all starts with drugmakers’ initial prices.
Drugmakers generally can charge as much as the market will bear because the U.S. government doesn’t regulate medicine prices, unlike most other countries.
The result, in part, is the highest drug prices in the world.
The U.S. spent $1,162 per person on prescription drugs in 2015, according to the Organization for Economic Cooperation and Development. That’s more than twice the $497 per person spent in the United Kingdom, which has a nationalized health care system.
Medicare is the largest purchaser of pre- scription drugs in the nation, covering 60 mil- lion seniors and Americans with disabilities, but it is barred by law from directly negotiat- ing lower prices with drugmakers. Democrats have long favored giving Medicare that power, but Republicans traditionally oppose the idea.
Allowing Medicare to negotiate prices is unacceptable to the powerful drug lobby, which has spent tens of millions of dollars since Trump’s inauguration to influence the Washington conversation around drug prices, including a high-profile TV advertising campaign portraying its scientists as medical trailblazers.
The drug industry’s top lobbying arm, Pharmaceutical Research and Manufacturers of America, spent nearly $26 million to sway federal decision makers last year, according to records tallied by the nonprofit Center for Responsive Politics. That spending total was the group’s highest since the 2009 congressio- nal battle that led to Obamacare.
___
AP Writer Jill Colvin contributed to this report.
___
Matthew Perrone can be followed on Twit- ter: @AP_FDAwriter
JOURNAL REVIEW | 11